Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
-
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
-
BUSINESS Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
-
REGULATORY CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
-
REGULATORY Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
-
REGULATORY CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
-
ACADEMIA ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
-
ORGANIZATION JGA to Prepare Transparency GLs
September 6, 2011
-
ORGANIZATION Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
-
REGULATORY Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
-
REGULATORY MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
-
REGULATORY Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
-
BUSINESS Daiichi Sankyo Espha Asks Patent Office to Invalidate Combination Patents for Takeda’s Actos
September 2, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…